2022-2023年美国猴痘患者中对替考维马特的耐药性
研究对美国2022年猴痘疫情期间临床分离的猴痘病毒进行基因组测序和表型检测,发现124株分离自68例患者的病毒中,96株来自46例患者具有耐药表型,耐药株多与接受多疗程替考维马特治疗的严重免疫抑制患者相关,而未治疗患者常规监测分离株多保持敏感,耐药病毒频率相对接受治疗总人数仍较低(<1%)。
要点
- 124株分离自68例患者的猴痘病毒中,96株来自46例患者具有耐药表型。
- 耐药株多与接受多疗程替考维马特治疗的严重免疫抑制猴痘患者相关。
- 未接受替考维马特治疗患者的常规监测分离株多保持敏感。
核心结论
- 耐药病毒频率相对接受替考维马特治疗的总患者数仍较低(<1%)。
研究设计与样本
- 对美国2022年多国猴痘疫情期间的临床分离株进行基因组测序,并用病毒细胞病变效应试验确定耐药表型。
主要发现
- 基因组测序鉴定出11个既往报道可致耐药的突变以及13个新突变。
- 检测124株分离自68例患者的病毒,其中96株来自46例患者具有耐药表型。
- 多数耐药分离株与接受多疗程替考维马特治疗的严重免疫抑制猴痘患者相关。
- 未接受替考维马特治疗患者的常规监测分离株多数仍保持敏感。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the 2022 multinational outbreak of monkeypox virus (MPXV) infection, the antiviral drug tecovirimat (TPOXX; SIGA Technologies, Inc., https://www.siga.com) was deployed in the United States on a large scale for the first time. The MPXV F13L gene homologue encodes the target of tecovirimat, and single amino acid changes in F13 are known to cause resistance to tecovirimat. Genomic sequencing identified 11 mutations previously reported to cause resistance, along with 13 novel mutations. Resistant phenotype was determined using a viral cytopathic effect assay. We tested 124 isolates from 68 patients; 96 isolates from 46 patients were found to have a resistant phenotype. Most resistant isolates were associated with severely immunocompromised mpox patients on multiple courses of tecovirimat treatment, whereas most isolates identified by routine surveillance of patients not treated with tecovirimat remained sensitive. The frequency of resistant viruses remains relatively low (<1%) compared with the total number of patients treated with tecovirimat.
引用
- Smith TG, Gigante CM, Wynn NT, et al. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023. Emerg Infect Dis. 2023. PMID: 37856204. doi:10.3201/eid2912.231146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。